Pegylated interferon beta performs well in clinical trial
Posted: Thu May 01, 2014 5:58 am
Tests of a new long-acting version of one of the oldest multiple sclerosis (MS) drugs on the market show it worked significantly better than placebo in reducing the number of patient relapses and developments of new or active lesions, researchers report. Most important, they add, the updated version was effective even though injections were given every two weeks instead of every other day, and it appears that fewer patients develop resistance to it...... Read More - http://www.ms-uk.org/PEGylatedinterferonbeta